Table 2.
In vitro antitumoral activity in HepG2 Cells of different nanoparticles with/without Dox.
| HepG2 Cells | |||
|---|---|---|---|
| Nanoparticles with Dox |
IC50 (µg/mL) | Nanoparticles without Dox |
IC50 (µg/mL) |
| LC tBSA-Dox | 1.05 ± 0.13 a | LC tBSA | ND |
| LC tBSA/BSALac-Dox | 0.7 ± 0.09 a | LC tBSA/BSALac | ND |
| HC tBSA-Dox | 1.04 ± 0.15 a | HC tBSA | ND |
| HC tBSA/BSALac-Dox | 0.59 ± 0.07 a | HC tBSA/BSALac | ND |
| Free Dox * | 1.90 ± 0.42 b | ||
IC50 values are average and standard deviation (±) for triplicate. Different letters (a and b) indicate statistical differences (p ≤ 0.05). ND: IC50 not determined at less than 200 μg/mL. * free Dox in PBS solution was used as a control.